Brain Inflammation Polypeptide Therapy After Hemorrhage

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for brain inflammation, particularly following intracerebral hemorrhage, are limited and often exacerbate the condition, leading to severe disability and poor clinical outcomes without effectively addressing neuroinflammation.

Innovation Solution

A protein or polypeptide with at least 75% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, derived from Ixodes ricinus salivary gland, is administered to prevent or treat brain inflammation, reducing neuroinflammation without increasing hemorrhage volume or edema.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Object-affected harmful factors

If current treatments for brain inflammation are administered, then inflammation is targeted, but hemorrhage volume increases and clinical outcomes worsen

Engineering Contradiction:

ImproveneuroinflammationVSAvoidclinical outcomes

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent uses a specific polypeptide (Ir-CPI or its variants) as an intermediary substance that selectively modulates the inflammatory response. This polypeptide acts as a mediator between the hemorrhage event and the inflammatory cascade, preventing excessive neuroinflammation while maintaining hemorrhage stability, thereby improving clinical outcomes without exacerbating bleeding

Inventive Principle:

Principle #24Intermediary (Mediator)

2Object-affected harmful factors

If aggressive anti-inflammatory treatment is applied, then neuroinflammation is reduced, but hemorrhage stability is compromised

Engineering Contradiction:

ImproveneuroinflammationVSAvoidhemorrhage volume

Core Design Contradiction:

Object-affected harmful factorsVSStability of the object's composition

Solution Approach 1:

The patent employs parameter changes by using specific polypeptide variants with modified amino acid sequences (at least 75% identity to SEQ ID NO: 1 or 2) that alter the inflammatory response parameters. These variants achieve effective neuroinflammation reduction while maintaining hemorrhage stability through optimized molecular characteristics that prevent excessive bleeding

Inventive Principle:

Principle #35Parameter changes

3Stability of the object's composition

If no treatment is administered, then hemorrhage stability is maintained, but neuroinflammation progresses leading to poor outcomes

Engineering Contradiction:

Improvehemorrhage volumeVSAvoidneuroinflammation

Core Design Contradiction:

Stability of the object's compositionVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary action by administering the polypeptide treatment within a specific time window (up to 120 hours, preferably 96 or 72 hours) after hemorrhage onset. This timely intervention prevents the progression of neuroinflammation before it causes severe damage, while the polypeptide's properties ensure hemorrhage stability is maintained throughout the treatment period

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS12544425B2Methods for preventing and treating brain inflammation

Publication Date: 2026.02.10 BIOXODES SA

AI summary

Methods for treating brain inflammation, including brain inflammation occurring or susceptible to occur after brain hemorrhage, which include the administration of a protein or polypeptide including a polypeptide having at least 75% sequence identity with the amino acid sequence SEQ ID NO: 1, or a pharmaceutical composition including the protein or polypeptide. Also, a method for preventing, reducing, decreasing, and/or inhibiting neuronal death, which includes the administration of a protein or polypeptide including a polypeptide having at least 75% sequence identity with the amino acid sequence SEQ ID NO: 1, or a pharmaceutical composition including the protein or polypeptide.